Background While the triglyceride-glucose (TyG) index is a measure of insulin resistance, its association with cardiovascular disease (CVD) has not been well elucidated. We evaluated the TyG index for prediction of CVDs in a prospective large communitybased cohort.
Methods Individuals 40 to 70 years old were prospectively followed for a median 15.6 years. The TyG index was calculated as the Ln [fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2]. CVDs included any acute myocardial infarction, coronary artery disease or cerebrovascular disease. We used a Cox proportional hazards model to estimate CVD risks according to quartiles of the TyG index and plotted the receiver operating characteristics curve for the incident CVD.
Results Among 8,511 subjects (age 51.9±8.8 years; 47.5% males), 931 (10.9%) had incident CVDs during the follow-up. After adjustment for age, sex, body mass index, diabetes mellitus, hypertension, total cholesterol, smoking, alcohol, exercise, and C-reactive protein, subjects in the highest TyG quartile had 36% increased risk of incident CVD compared with the lowest TyG quartile (hazard ratio, 1.36; 95% confidence interval, 1.10 to 1.68). Carotid plaque, assessed by ultrasonography was more frequent in subjects in the higher quartile of TyG index (P for trend=0.049 in men and P for trend <0.001 in women). The TyG index had a higher predictive power for CVDs than the homeostasis model assessment of insulin resistance (HOMA-IR) (area under the curve, 0.578 for TyG and 0.543 for HOMA-IR). Adding TyG index on diabetes or hypertension alone gave sounder predictability for CVDs.
Conclusion The TyG index is independently associated with future CVDs in 16 years of follow-up in large, prospective Korean cohort.
Background Post-transplant diabetes mellitus (PTDM) is a risk factor for poor outcomes after kidney transplantation (KT). However, the outcomes of KT have improved recently. Therefore, we investigated whether PTDM is still a risk factor for mortality, major atherosclerotic cardiovascular events (MACEs), and graft failure in KT recipients.
Methods We studied a retrospective cohort of KT recipients (between 1994 and 2017) at a single tertiary center, and compared the rates of death, MACEs, overall graft failure, and death-censored graft failure after KT between patients with and without PTDM using Kaplan-Meier analysis and a Cox proportional hazard model.
Results Of 571 KT recipients, 153 (26.8%) were diagnosed with PTDM. The mean follow-up duration was 9.6 years. In the Kaplan- Meier analysis, the PTDM group did not have a significantly increased risk of death or four-point MACE compared with the non-diabetes mellitus group (log-rank test, P=0.957 and P=0.079, respectively). Multivariate Cox proportional hazard models showed that PTDM did not have a negative impact on death or four-point MACE (P=0.137 and P=0.181, respectively). In addition, PTDM was not significantly associated with overall or death-censored graft failure. However, patients with a long duration of PTDM had a higher incidence of four-point MACE.
Conclusion Patient survival and MACEs were comparable between groups with and without PTDM. However, PTDM patients with long duration diabetes were at higher risk of cardiovascular disease.
Diabetes, Obesity and Metabolism Big Data Articles (National Health Insurance Service Database)
Background This study aimed to investigate the long-term effects of diabetes drug costs on cardiovascular (CV) events and death.
Methods This retrospective observational study used data from 2009 to 2018 from the National Health Insurance in Korea. Among the patients with type 2 diabetes, those taking antidiabetic drugs and who did not have CV events until 2009 were included. Patients were divided into quartiles (Q1 [lowest]–4 [highest]) according to the 2009 diabetes drug cost. In addition, the 10-year incidences of CV events (non-fatal myocardial infarction, stroke, hospitalization for heart failure, and coronary revascularization) and CV death (death due to CV events) were analyzed.
Results A total of 441,914 participants were enrolled (median age, 60 years; men, 57%). CV events and death occurred in 28.1% and 8.36% of the patients, respectively. The 10-year incidences of CV events and deaths increased from Q1 to 4. After adjusting for sex, age, income, type of diabetes drugs, comorbidities, and smoking and drinking status, the risk of CV events significantly increased according to the sequential order of the cost quartiles. In contrast, the risk of CV death showed a U-shaped pattern, which was the lowest in Q3 (hazard ratio [HR], 0.953; 95% confidence interval [CI], 0.913 to 0.995) and the highest in Q4 (HR, 1.266; 95% CI, 1.213 to 1.321).
Conclusion Diabetes drug expenditure affects 10-year CV events and mortality. Therefore, affording an appropriate diabetes drug cost at a similar risk of CV is an independent protective factor against CV death.
Citations
Citations to this article as recorded by
Impact of mental disorders on the risk of heart failure among Korean patients with diabetes: a cohort study Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee Cardiovascular Diabetology.2023;[Epub] CrossRef
High levels of triglycerides (TG) and triglyceride-rich lipoproteins (TGRLs) confer a residual risk of cardiovascular disease after optimal low-density lipoprotein cholesterol (LDL-C)–lowering therapy. Consensus has been made that LDL-C is a non-arguable primary target for lipid lowering treatment, but the optimization of TGRL for reducing the remnant risk of cardiovascular diseases is urged. Omega-3 fatty acids and fibrates are used to reduce TG levels, but many patients still have high TG and TGRL levels combined with low high-density lipoprotein concentration that need to be ideally treated. Lipoprotein lipase (LPL) is a key regulator for TGs that hydrolyzes TGs to glycerol and free fatty acids in lipoprotein particles for lipid storage and consumption in peripheral organs. A deeper understanding of human genetics has enabled the identification of proteins regulating the LPL activity, which include the apolipoproteins and angiopoietin-like families. Novel therapeutic approach such as antisense oligonucleotides and monoclonal antibodies that regulate TGs have been developed in recent decades. In this article, we focus on the biology of LPL and its modulators and review recent clinical application, including genetic studies and clinical trials of novel therapeutics. Optimization of LPL activity to lower TG levels could eventually reduce incident atherosclerotic cardiovascular disease in conjunction with successful LDL-C reduction.
Citations
Citations to this article as recorded by
High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis Franziska Schmalz, Janett Fischer, Hamish Innes, Stephan Buch, Christine Möller, Madlen Matz-Soja, Witigo von Schönfels, Benjamin Krämer, Bettina Langhans, Alexandra Klüners, Michael Soyka, Felix Stickel, Jacob Nattermann, Christian P. Strassburg, Thomas JHEP Reports.2023; 5(4): 100684. CrossRef
Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations Dieter Lütjohann, Hans-Ulrich Klör, Frans Stellaard Nutrients.2023; 15(9): 2202. CrossRef
Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression Tien-Yuan Wu, Ni Tien, Cheng-Li Lin, Yu-Cun Cheah, Chung Y. Hsu, Fuu-Jen Tsai, Yi-Jen Fang, Yun-Ping Lim Frontiers in Medicine.2023;[Epub] CrossRef
Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux Alejandro Gugliucci Journal of Clinical Medicine.2023; 12(13): 4399. CrossRef
Sugar and Dyslipidemia: A Double-Hit, Perfect Storm Alejandro Gugliucci Journal of Clinical Medicine.2023; 12(17): 5660. CrossRef
Background High cardiorespiratory fitness (CRF) protects against age-related diseases. However, the mechanisms mediating the protective effect of high intrinsic CRF against metabolic, cardiac, and brain impairments in non-obese versus obese conditions remain incompletely understood. We aimed to identify the mechanisms through which high intrinsic CRF protects against metabolic, cardiac, and brain impairments in non-obese versus obese untrained rats.
Methods Seven-week-old male Wistar rats were divided into two groups (n=8 per group) to receive either a normal diet or a highfat diet (HFD). At weeks 12 and 28, CRF, carbohydrate and fatty acid oxidation, cardiac function, and metabolic parameters were evaluated. At week 28, behavior tests were performed. At the end of week 28, rats were euthanized to collect heart and brain samples for molecular studies.
Results The obese rats exhibited higher values for aging-related parameters than the non-obese rats, indicating that they experienced obesity-induced premature aging. High baseline CRF levels were positively correlated with several favorable metabolic, cardiac, and brain parameters at follow-up. Specifically, the protective effects of high CRF against metabolic, cardiac, and brain impairments were mediated by the modulation of body weight and composition, the lipid profile, substrate oxidation, mitochondrial function, insulin signaling, autophagy, apoptosis, inflammation, oxidative stress, cardiac function, neurogenesis, blood-brain barrier, synaptic function, accumulation of Alzheimer’s disease-related proteins, and cognition. Interestingly, this effect was more obvious in HFD-fed rats.
Conclusion The protective effect of high CRF is mediated by the modulation of several mechanisms. These effects exhibit greater efficacy under conditions of obesity-induced premature aging.
Citations
Citations to this article as recorded by
Interplay between obesity and aging on myocardial geometry and function: Role of leptin-STAT3-stress signaling Wei Jin, Fei Tu, Feng Dong, Qinqin Deng, Miyesaier Abudureyimu, Wei Yu, Guo-jun Cai, Jian-ming Pei, Zhaohui Pei, Jun Ren Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(2): 130281. CrossRef
Epidemiological, mechanistic, and practical bases for assessment of cardiorespiratory fitness and muscle status in adults in healthcare settings Jaime A. Gallo-Villegas, Juan C. Calderón European Journal of Applied Physiology.2023; 123(5): 945. CrossRef
A plethora of negative long-term outcomes have been associated with congenital adrenal hyperplasia (CAH). The causes are multiple and involve supra-physiological gluco- and mineralocorticoid replacement, excess adrenal androgens both intrauterine and postnatal, elevated steroid precursor and adrenocorticotropic hormone levels, living with a congenital condition as well as the proximity of the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene to other genes. This review aims to discuss the different long-term outcomes of CAH.
Citations
Citations to this article as recorded by
Congenital adrenal hyperplasia: New biomarkers and adult treatments Bleuenn Dreves, Yves Reznik, Antoine Tabarin Annales d'Endocrinologie.2023; 84(4): 472. CrossRef
Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management Kyriakie Sarafoglou, Deborah P Merke, Nicole Reisch, Hedi Claahsen-van der Grinten, Henrik Falhammar, Richard J Auchus The Journal of Clinical Endocrinology & Metabolism.2023; 108(9): 2154. CrossRef
Impact of Newborn Screening on Adult Height in Patients With Congenital Adrenal Hyperplasia (CAH) Heike Hoyer-Kuhn, Alexander J Eckert, Gerhard Binder, Walter Bonfig, Angelika Dübbers, Stefan Riedl, Joachim Woelfle, Helmuth G Dörr, Reinhard W Holl The Journal of Clinical Endocrinology & Metabolism.2023;[Epub] CrossRef
Specialty grand challenge in adrenal endocrinology Henrik Falhammar Frontiers in Endocrinology.2023;[Epub] CrossRef
Contexts of care for people with differences of sex development Alexandra E. Kulle, Martina Jürgensen, Ulla Döhnert, Lisa Malich, Louise Marshall, Olaf Hiort Medizinische Genetik.2023; 35(3): 181. CrossRef
Approach of Heterogeneous Spectrum Involving 3beta-Hydroxysteroid Dehydrogenase 2 Deficiency Andreea Gabriela Nicola, Mara Carsote, Ana-Maria Gheorghe, Eugenia Petrova, Alexandru Dan Popescu, Adela Nicoleta Staicu, Mihaela Jana Țuculină, Cristian Petcu, Ionela Teodora Dascălu, Tiberiu Tircă Diagnostics.2022; 12(9): 2168. CrossRef
Effetti di Crinecerfont sulla secrezione di ACTH nell’iperplasia surrenalica congenita: uno studio di fase 2 Marianna Rita Stancampiano, Silvia Laura Carla Meroni, Giovanna Weber, Gianni Russo L'Endocrinologo.2022; 23(6): 662. CrossRef
The world is suffering from a rapid increase in the number of people with diabetes due to the increased prevalence of obesity and lengthened life span. Since the development of insulin thanks to the efforts of Prof. Banting and Dr. Best in 1922, for which they won the Nobel Prize, remarkable developments in anti-diabetic medications have dramatically lengthened the lifespan of patients with diabetes. However, the control rate of hyperglycemia in patients with diabetes remains unsatisfactory, since glycemic control requires both medication and lifestyle modifications to slow the deterioration of pancreatic beta-cell function and prevent diabetic complications. From the initial “triumvirate” to the “ominous octet,” and now the “egregious eleven,” the number of organs recognized as being involved in hyperglycemia and diabetes has increased with the development of anti-diabetic medications. Recent unexpected results from outcome trials of anti-diabetic medications have enabled anti-diabetic medications to be indicated for the prevention of chronic kidney disease and heart failure, even in patients without diabetes. In this review, I would like to summarize the extra-glycemic effects of anti-diabetic medications.
Citations
Citations to this article as recorded by
To do one and to get more: Part I. Diabetes and bone Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee Journal of the Chinese Medical Association.2022; 85(10): 965. CrossRef
Original Articles
Diabetes, Obesity and Metabolism Big Data Articles (National Health Insurance Service Database)
Background Diabetes is a leading cause of death that is responsible for 1.6 million annual deaths worldwide. However, the life expectancy and age at death of people with diabetes have been a matter of debate.
Methods The National Health Insurance Service claims database, merged with death records from the National Statistical Information Service in Korea from 2006 to 2018, was analyzed.
Results In total, 1,432,567 deaths were collected. The overall age at death increased by 0.44 and 0.26 year/year in the diabetes and control populations, respectively. The disparity in the mean age at death between the diabetes and control populations narrowed from 5.2 years in 2006 to 3.0 years in 2018 (p<0.001). In a subgroup analysis according to the presence of comorbid diseases, the number and proportion of deaths remained steady in the group with diabetes only, but steadily increased in the groups with diabetes combined with dyslipidemia and/or hypertension. Compared to the control population, the increase in the mean death age was higher in the population with diabetes. This trend was more prominent in the groups with dyslipidemia and/or hypertension than in the diabetes only group. Deaths from vascular disease and diabetes decreased, whereas deaths from cancer and pneumonia increased. The decline in the proportion of deaths from vascular disease was greater in the diabetes groups with hypertension and/or dyslipidemia than in the control population.
Conclusion The age at death in the population with diabetes increased more steeply and reached a comparable level to those without diabetes.
Citations
Citations to this article as recorded by
Analysis of Cause-of-Death Mortality in Children and Young Adults with Diabetes: A Nationwide 10-Year Follow-Up Cohort Study Iee-Ho Choi, Sang-Woo Yeom, Sun-Young Kim, Jihye You, Jong-Seung Kim, Minsun Kim Children.2023; 10(2): 358. CrossRef
Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018 Sun Ok Song, Eugene Han, Kang Ju Son, Bong-Soo Cha, Byung-Wan Lee Journal of Clinical Medicine.2023; 12(9): 3160. CrossRef
Background The role of aspirin in primary cardiovascular disease prevention in patients with diabetes remains controversial. However, some studies have suggested beneficial effects of cilostazol on cardiovascular disease in patients with diabetes. We prospectively investigated the antiplatelet effects of cilostazol compared with aspirin in patients with diabetes and cardiovascular risk factors.
Methods We randomly assigned 116 patients with type 2 diabetes and cardiovascular risk factors but no evident cardiovascular disease to receive aspirin at a dose of 100 mg or cilostazol at a dose of 200 mg daily for 14 days. The primary efficacy outcome was antiplatelet effects of aspirin and cilostazol assessed with the VerifyNow system (aspirin response units [ARU]) and PFA-100 (closure time [CT]). Secondary outcomes were changes of clinical laboratory data (ClinicalTrials.gov Identifier: NCT02933788).
Results After 14 days, there was greater decrease in ARU in aspirin (–28.9%±9.9%) compared cilostazol (–0.4%±7.1%, P<0.001) and was greater increase in CT in aspirin (99.6%±63.5%) compared cilostazol (25.7%±54.1%, P<0.001). The prevalence of aspirin resistance was 7.5% according to VerifyNow (defined by ARU ≥550) and 18.9% according to PFA-100 (CT <192 seconds). Compared with aspirin, cilostazol treatment was associated with increased high density lipoprotein cholesterol (7.1%±12.7% vs. 4.2%±18.0%, P=0.006) and decreased triglycerides (–9.4%±33.7% vs. 4.4%±17.57%, P=0.016). However, there were no significant changes in total and low density lipoprotein cholesterol, C-reactive protein level, and cluster of differentiation 40 ligand between cilostazol and aspirin groups.
Conclusion Aspirin showed better antiplatelet effects assessed with VerifyNow and PFA-100 compared with cilostazol. However, there were favorable changes in atherogenic dyslipidemia only in the cilostazol.
The prevalence of obesity is rapidly increasing worldwide. Obesity should not be understood only as the accumulation of fat in the body, but instead as a phenomenon that exerts different effects on our health according to the place of fat deposition and its stability. Obesity is the starting point of most metabolic diseases, such as diabetes, hypertension, metabolic syndrome, sleep apnea, and eventually cardiovascular disease. There are different kinds of obesity, ranging from simple obesity to sarcopenic obesity. The main purpose of intervening to address obesity is to decrease the ultimate consequence of obesity—namely, cardiovascular disease. The main mechanism through which obesity, especially abdominal obesity, increases cardiovascular risk is the obesity-induced derangement of metabolic health, leading to the development of metabolic diseases such as diabetes, non-alcoholic fatty liver disease, and metabolic syndrome, which are the main initiators of vascular damage. In this review, I discuss the influence of various types of obesity on the risk of metabolic diseases, and how these diseases increase cardiovascular disease risk.
Citations
Citations to this article as recorded by
Mechanistic insights into dietary (poly)phenols and vascular dysfunction-related diseases using multi-omics and integrative approaches: Machine learning as a next challenge in nutrition research Dragan Milenkovic, Tatjana Ruskovska Molecular Aspects of Medicine.2023; 89: 101101. CrossRef
Pharmacological Support for the Treatment of Obesity—Present and Future Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, Monika Różycka-Kosmalska, Tadeusz Pietras Healthcare.2023; 11(3): 433. CrossRef
Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes Donna H. Ryan, John E. Deanfield, Stephan Jacob Cardiovascular Endocrinology & Metabolism.2023; 12(1): e0279. CrossRef
Adipopenia is associated with osteoporosis in community-dwelling non-underweight adults independent of sarcopenia Seunghyun Lee, Kyoungmyoung Ko, Sungjae Shin, Hye Sun Park, Namki Hong, Yumie Rhee Archives of Osteoporosis.2023;[Epub] CrossRef
Design, synthesis and evaluation of 2-pyrimidinylindole derivatives as anti-obesity agents by regulating lipid metabolism Shi-Yao Guo, Li-Yuan Wei, Bing-Bing Song, Yu-Tao Hu, Zhi Jiang, Dan-Dan Zhao, Yao-Hao Xu, Yu-Wei Lin, Shu-Min Xu, Shuo-Bin Chen, Zhi-Shu Huang European Journal of Medicinal Chemistry.2023; 260: 115729. CrossRef
Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent Nutrients.2022; 14(14): 2795. CrossRef
Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Shou-Dong Guo Frontiers in Nutrition.2022;[Epub] CrossRef
Predictive Roles of Basal Metabolic Rate and Body Water Distribution in Sarcopenia and Sarcopenic Obesity: The link to Carbohydrates Lizheng Guan, Tiantian Li, Xuan Wang, Kang Yu, Rong Xiao, Yuandi Xi Nutrients.2022; 14(19): 3911. CrossRef
Metabolic risk factors in patients with comorbidity in Ufa primary health care O.V. Molchanova, A.V. Mamaeva, A.R. Dunayeva, Z.A. Lust, E.M. Faskhetdinova, R.N. Shepel, D.O. Orlov, L.M. Zhamalov, G.F. Andreeva, O.M. Drapkina Profilakticheskaya meditsina.2022; 25(9): 39. CrossRef
Assessment of Vitamin D Levels in Relation to Statin Therapy in Elderly Hypertensive Patients with Comorbidities Kinga-Ilona Nyulas, Zsuzsánna Simon-Szabó, Zoltán Preg, Sándor Pál, Arundhati Sharma, Tünde Pál, Márta Germán-Salló, Enikő Nemes-Nagy Journal of Interdisciplinary Medicine.2022; 7(4): 88. CrossRef
Original Articles
Diabetes, Obesity and Metabolism Big Data Articles (National Health Insurance Service Database)
Background Metabolic abnormalities, such as impaired fasting glucose (IFG), are dynamic phenomena; however, it is unclear whether the timing of IFG exposure and cumulative exposure to IFG are related to cardiovascular disease (CVD) and mortality risk.
Methods Data were extracted from a nationwide population-based cohort in South Korea for adults (n=2,206,679) who were free of diabetes and had 4 years of consecutive health examination data. Fasting blood glucose levels of 100 to 125 mg/dL were defined as IFG, and the number of IFG diagnoses for each adult in the 4-year period was tabulated as the IFG exposure score (range, 0 to 4). Adults with persistent IFG for the 4-year period received a score of 4.
Results The median follow-up was 8.2 years. There were 24,820 deaths, 13,502 cases of stroke, and 13,057 cases of myocardial infarction (MI). IFG exposure scores of 1, 2, 3, and 4 were associated with all-cause mortality (multivariable-adjusted hazard ratio [aHR], 1.11; 95% confidence interval [CI], 1.08 to 1.15; aHR, 1.16; 95% CI, 1.12 to 1.20; aHR, 1.20; 95% CI, 1.15 to 1.25; aHR, 1.18; 95% CI, 1.11 to 1.25, respectively) compared with an IFG exposure score of 0. Adjusting for hypertension and dyslipidemia attenuated the slightly increased risk of MI or stroke associated with high IFG exposure scores, but significant associations for allcause mortality remained.
Conclusion The intensity of IFG exposure was associated with an elevated risk of all-cause mortality, independent of cardiovascular risk factors. The association between IFG exposure and CVD risk was largely mediated by the coexistence of dyslipidemia and hypertension.
Citations
Citations to this article as recorded by
A nationwide cohort study on diabetes severity and risk of Parkinson disease Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim npj Parkinson's Disease.2023;[Epub] CrossRef
Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim Respiratory Research.2023;[Epub] CrossRef
Construction and Validation of a Model for Predicting Impaired Fasting Glucose Based on More Than 4000 General Population Cuicui Wang, Xu Zhang, Chenwei Li, Na Li, Xueni Jia, Hui Zhao International Journal of General Medicine.2023; Volume 16: 1415. CrossRef
Factors Affecting High Body Weight Variability Kyungdo Han, Mee Kyoung Kim Journal of Obesity & Metabolic Syndrome.2023; 32(2): 163. CrossRef
Exposure to perfluoroalkyl and polyfluoroalkyl substances and risk of stroke in adults: a meta-analysis Min Cheol Chang, Seung Min Chung, Sang Gyu Kwak Reviews on Environmental Health.2023;[Epub] CrossRef
A Longitudinal Retrospective Observational Study on Obesity Indicators and the Risk of Impaired Fasting Glucose in Pre- and Postmenopausal Women Myung Ji Nam, Hyunjin Kim, Yeon Joo Choi, Kyung-Hwan Cho, Seon Mee Kim, Yong-Kyun Roh, Kyungdo Han, Jin-Hyung Jung, Yong-Gyu Park, Joo-Hyun Park, Do-Hoon Kim Journal of Clinical Medicine.2022; 11(10): 2795. CrossRef
Current Trends of Big Data Research Using the Korean National Health Information Database Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee Diabetes & Metabolism Journal.2022; 46(4): 552. CrossRef
Lipid cutoffs for increased cardiovascular disease risk in non-diabetic young people Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Kun-Ho Yoon, Seung-Hwan Lee European Journal of Preventive Cardiology.2022; 29(14): 1866. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef
Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk Seohyun Kim, Gyuri Kim, Jae Hyeon Kim Scientific Reports.2022;[Epub] CrossRef
Diabetes, Obesity and Metabolism Big Data Articles (National Health Insurance Service Database)
Background We estimated the effect of obesity on the incidence of cardiovascular disease (CVD) and mortality in women according to menopausal status.
Methods Women aged 40 to 69 years under routine health check-ups provided by the National Health Insurance Service in 2009 were followed up till 2018 (n=2,208,559).
Results In premenopausal women, a significant increment of mortality rate was found in underweight and obesity class II (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.31 to 1.67; and HR, 1.25; 95% CI, 1.12 to 1.39) compared to normal body mass index (BMI); overweight and obesity class I did not affect mortality rate. In postmenopausal women, obesity as well as overweight status reduced the risk of mortality compared to normal BMI (HR, 0.86; 95% CI, 0.83 to 0.88; and HR, 0.84; 95% CI, 0.82 to 0.86). By contrast, there was a linear association between CVD and BMI above the normal range irrespective of menopausal status, which was attenuated in diabetic women.
Conclusion The current study replicated the J-shaped relationship between BMI and mortality, being more prominent in the postmenopausal group. The risk of CVD was linearly increased as BMI was increased above the normal range irrespective of menopausal status.
Citations
Citations to this article as recorded by
A nationwide cohort study on diabetes severity and risk of Parkinson disease Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim npj Parkinson's Disease.2023;[Epub] CrossRef
Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus Min Kyong Moon, Junghyun Noh, Eun-Jung Rhee, Sang Hyun Park, Hyeon Chang Kim, Byung Jin Kim, Hae Jin Kim, Seonghoon Choi, Jin Oh Na, Young Youl Hyun, Bum Joon Kim, Kyung-Do Han, In-Kyung Jeong Diabetes & Metabolism Journal.2023; 47(1): 45. CrossRef
The effect of menopause on cardiovascular risk factors according to body mass index in middle-aged Korean women Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Aysha Almas PLOS ONE.2023; 18(3): e0283393. CrossRef
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim Alimentary Pharmacology & Therapeutics.2023; 58(3): 322. CrossRef
Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim Respiratory Research.2023;[Epub] CrossRef
Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes Mee Kyoung Kim, Kyungdo Han, Bongsung Kim, Jinyoung Kim, Hyuk-Sang Kwon Scientific Reports.2022;[Epub] CrossRef
Non-pharmacologic treatment for obesity Bo Kyung Koo Journal of the Korean Medical Association.2022; 65(7): 400. CrossRef
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.
Citations
Citations to this article as recorded by
Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD Ayodele Odutayo, Adeera Levin Clinical Journal of the American Society of Nephrology.2023; 18(5): 557. CrossRef
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim Endocrinology and Metabolism.2023; 38(1): 43. CrossRef
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung Endocrinology and Metabolism.2023; 38(4): 359. CrossRef
Management of CKD Nimrit Goraya, Jennifer D. Moran Nephrology Self-Assessment Program.2022; 21(2): 146. CrossRef
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy Peter Kolkhof, Amer Joseph, Ulrich Kintscher Pharmacological Research.2021; 172: 105859. CrossRef
Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter Journal of the American Heart Association.2021;[Epub] CrossRef
Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz touchREVIEWS in Endocrinology.2021; 17(2): 84. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review Jorge I. Fonseca-Correa, Ricardo Correa-Rotter Frontiers in Medicine.2021;[Epub] CrossRef
Original Article
Clinical Study Big Data Articles (National Health Insurance Service Database)
Background Results regarding the cardiovascular (CV) effects of dipeptidyl peptidase-4 (DPP-4) inhibitors are inconsistent. This study aimed to assess the effects of teneligliptin, a DPP-4 inhibitor, on the risk of major CV outcomes in type 2 diabetes mellitus (T2DM) patients compared to sulfonylurea.
Methods From January 1, 2015 to December 31, 2017, we conducted a retrospective cohort study using the Korean National Health Insurance Service database. A total of 6,682 T2DM patients who were newly prescribed DPP-4 inhibitors or sulfonylurea were selected and matched in a 1:1 ratio by propensity score. The hazard ratios (HRs) for all-cause mortality, hospitalization for heart failure (HHF), all-cause mortality or HHF, myocardial infarction (MI), stroke, and hypoglycemia were assessed.
Results During 641 days of follow-up, the use of teneligliptin was not associated with an increased risk of all-cause mortality (HR, 1.00; 95% confidence interval [CI], 0.85 to 1.19), HHF (HR, 0.99; 95% CI, 0.86 to 1.14), all-cause mortality or HHF (HR, 1.02; 95% CI, 0.90 to 1.14), MI (HR, 0.90; 95% CI, 0.68 to 1.20), and stroke (HR, 1.00; 95% CI, 0.86 to 1.17) compared to the use of sulfonylurea. However, it was associated with a significantly lower risk of hypoglycemia (HR, 0.68; 95% CI, 0.49 to 0.94) compared to sulfonylurea therapy.
Conclusion Among T2DM patients, teneligliptin therapy was not associated with an increased risk of CV events including HHF, but was associated with a lower risk of hypoglycemia compared to sulfonylurea therapy.
Citations
Citations to this article as recorded by
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy Journal of Endocrinological Investigation.2023; 46(5): 855. CrossRef
Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study Harmanjit Singh, Ekta Arora, Seerat Narula, Mandeep Singla, Armaan Otaal, Jatin Sharma Expert Review of Endocrinology & Metabolism.2023; 18(4): 347. CrossRef
Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022. CrossRef
Increased fat mass is an established risk factor for the cardiometabolic diseases type 2 diabetes and cardiovascular disease (CVD) and is associated with increased risk of all-cause and CVD mortality. However, also very low fat mass associates with such an increased risk. Whether impaired metabolic health, characterized by hypertension, dyslipidemia, hyperglycemia, insulin resistance, and subclinical inflammation, may explain part of the elevated risk of cardiometabolic diseases that is found in many subjects with very low fat mass, as it does in many obese subjects, is unknown. An important pathomechanism of impaired metabolic health is disproportionate fat distribution. In this article the risk of cardiometabolic diseases and mortality in subjects with metabolically healthy and unhealthy normal weight and obesity is summarized. Furthermore, the change of metabolic health during a longer period of follow-up and its impact on cardiometabolic diseases is being discussed. Finally, the implementation of the concept of metabolic health in daily clinical practice is being highlighted.
Citations
Citations to this article as recorded by
Metabolically Healthy Obesity: An Eye-opener Purushothaman Padmanabhan, Nagendram Dinakaran, Somnath Verma, S Keerthana Gastroenterology, Hepatology and Endoscopy Practice.2023; 3(1): 1. CrossRef
Effect of metabolic health and obesity on all-cause death and CVD incidence in Korean adults: a retrospective cohort study Ye-Seul Kim, Sang-Jun Shin, Yonghwan Kim, Joungyoun Kim, Hee-Taik Kang Scientific Reports.2023;[Epub] CrossRef
Coffee and metabolic phenotypes: A cross-sectional analysis of the Japan multi-institutional collaborative cohort (J-MICC) study Takeshi Watanabe, Kokichi Arisawa, Tien Van Nguyen, Masashi Ishizu, Sakurako Katsuura-Kamano, Asahi Hishida, Takashi Tamura, Yasufumi Kato, Rieko Okada, Rie Ibusuki, Chihaya Koriyama, Sadao Suzuki, Takahiro Otani, Teruhide Koyama, Satomi Tomida, Kiyonori Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(3): 620. CrossRef
Metabolically unhealthy phenotype in adults with normal weight: Is cardiometabolic health worse off when compared to adults with obesity? Myong-Won Seo, Joon Young Kim Obesity Research & Clinical Practice.2023; 17(2): 116. CrossRef
Association between metabolic obesity phenotypes and multiple myeloma hospitalization burden: A national retrospective study Yue Zhang, Xiude Fan, Chunhui Zhao, Zinuo Yuan, Yiping Cheng, Yafei Wu, Junming Han, Zhongshang Yuan, Yuanfei Zhao, Keke Lu Frontiers in Oncology.2023;[Epub] CrossRef
Metabolically healthy obesity: Misleading phrase or healthy phenotype? Cem Tanriover, Sidar Copur, Abduzhappar Gaipov, Batu Ozlusen, Rustu E. Akcan, Masanari Kuwabara, Mads Hornum, Daniel H. Van Raalte, Mehmet Kanbay European Journal of Internal Medicine.2023; 111: 5. CrossRef
Prevalence of combined metabolic health and weight status by various diagnosis criteria and association with cardiometabolic disease in Korean adults Myong-Won Seo, Jung-Min Lee, Hyun Chul Jung Obesity Research & Clinical Practice.2023; 17(2): 137. CrossRef
Precision medicine in complex diseases—Molecular subgrouping for improved prediction and treatment stratification Åsa Johansson, Ole A. Andreassen, Søren Brunak, Paul W. Franks, Harald Hedman, Ruth J. F. Loos, Benjamin Meder, Erik Melén, Craig E. Wheelock, Bo Jacobsson Journal of Internal Medicine.2023; 294(4): 378. CrossRef
Lipid droplet biogenesis and functions in health and disease Armella Zadoorian, Ximing Du, Hongyuan Yang Nature Reviews Endocrinology.2023; 19(8): 443. CrossRef
Molecular Mechanisms for the Vicious Cycle between Insulin Resistance and the Inflammatory Response in Obesity Dariusz Szukiewicz International Journal of Molecular Sciences.2023; 24(12): 9818. CrossRef
Insulin Resistance Is the Main Characteristic of Metabolically Unhealthy Obesity (MUO) Associated with NASH in Patients Undergoing Bariatric Surgery Sophia M. Schmitz, Sebastian Storms, Alexander Koch, Christine Stier, Andreas Kroh, Karl P. Rheinwalt, Sandra Schipper, Karim Hamesch, Tom F. Ulmer, Ulf P. Neumann, Patrick H. Alizai Biomedicines.2023; 11(6): 1595. CrossRef
Hyperleptinemia as a marker of various phenotypes of obesity and overweight in women with rheumatoid arthritis and systemic lupus erythematosus L. V. Kondrateva, Yu. N. Gorbunova, T. A. Panafidina, T. V. Popkova Rheumatology Science and Practice.2023; 61(3): 339. CrossRef
Metabolically unhealthy individuals, either with obesity or not, have a higher risk of critical coronavirus disease 2019 outcomes than metabolically healthy individuals without obesity Nam Hoon Kim, Kyeong Jin Kim, Jimi Choi, Sin Gon Kim Metabolism.2022; 128: 154894. CrossRef
Associations between obesity, metabolic syndrome, and endometrial cancer risk in East Asian women Boyoung Park Journal of Gynecologic Oncology.2022;[Epub] CrossRef
Insulin and cancer: a tangled web Brooks P. Leitner, Stephan Siebel, Ngozi D. Akingbesote, Xinyi Zhang, Rachel J. Perry Biochemical Journal.2022; 479(5): 583. CrossRef
Relationships Between Metabolic Body Composition Status and Rapid Kidney Function Decline in a Community-Based Population: A Prospective Observational Study Shao-Chi Chu, Po-Hsi Wang, Kuan-Ying Lu, Chia-Chun Ko, Yun-Hsuan She, Chin-Chan Lee, I-Wen Wu, Chiao-Yin Sun, Heng-Jung Hsu, Heng-Chih Pan Frontiers in Public Health.2022;[Epub] CrossRef
Dissecting the clinical relevance of polygenic risk score for obesity—a cross-sectional, longitudinal analysis Eun Kyung Choe, Manu Shivakumar, Seung Mi Lee, Anurag Verma, Dokyoon Kim International Journal of Obesity.2022; 46(9): 1686. CrossRef
Metabolic and Obesity Phenotype Trajectories in Taiwanese Medical Personnel Hsin-Yun Chang, Jer-Hao Chang, Yin-Fan Chang, Chih-Hsing Wu, Yi-Ching Yang International Journal of Environmental Research and Public Health.2022; 19(13): 8184. CrossRef
Sex Differences in Cardiovascular Impact of Early Metabolic Impairment: Interplay between Dysbiosis and Adipose Inflammation Haneen S. Dwaib, Ibrahim AlZaim, Ghina Ajouz, Ali H. Eid, Ahmed El-Yazbi Molecular Pharmacology.2022; 102(1): 60. CrossRef
Reduced leukocyte mitochondrial copy number in metabolic syndrome and metabolically healthy obesity Rachel Agius, Nikolai Paul Pace, Stephen Fava Frontiers in Endocrinology.2022;[Epub] CrossRef
Changes in BMI and physical activity from youth to adulthood distinguish normal-weight, metabolically obese adults from those who remain healthy A. Viitasalo, K. Pahkala, T. Lehtimäki, JSA. Viikari, TH. Tammelin, O. Raitakari, TO. Kilpeläinen Frontiers in Endocrinology.2022;[Epub] CrossRef
Pathogenesis, Murine Models, and Clinical Implications of Metabolically Healthy Obesity Yun Kyung Cho, Yoo La Lee, Chang Hee Jung International Journal of Molecular Sciences.2022; 23(17): 9614. CrossRef
Metabolically healthy obesity: it is time to consider its dynamic changes Yun Kyung Cho, Chang Hee Jung Cardiovascular Prevention and Pharmacotherapy.2022; 4(4): 123. CrossRef
Obesity as a Risk Factor for Breast Cancer—The Role of miRNA Karolina Hanusek, Jakub Karczmarski, Anna Litwiniuk, Katarzyna Urbańska, Filip Ambrozkiewicz, Andrzej Kwiatkowski, Lidia Martyńska, Anita Domańska, Wojciech Bik, Agnieszka Paziewska International Journal of Molecular Sciences.2022; 23(24): 15683. CrossRef
Propensity Score–Matching Sleeve Gastrectomy (SG) vs. Gastric Bypass (RYGB) in Patients ≥ 60 Years Omar Thaher, Stefanie Wolf, Martin Hukauf, Christine Stroh Obesity Surgery.2021; 31(6): 2682. CrossRef
Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women Boyoung Park, Soyeoun Kim, Hayoung Kim, Chihwan Cha, Min Sung Chung British Journal of Cancer.2021; 125(12): 1718. CrossRef